FTSE MIB
33.666,30 +357,53 (+1,07%) Dow Jones
39.150,33 +15,53 (+0,04%) Nasdaq
17.689,36 -32,24 (-0,18%) Nikkei 225
38.804,65 +208,18 (+0,54%) Petrolio
80,96 +0,23 (+0,28%) Bitcoin EUR
57.267,49 -2.661,16 (-4,44%)
Virios Therapeutics, Inc. (VIRI)
Preborsa:
| Chiusura precedente | 0,2600 |
| Aperto | 0,2600 |
| Denaro | 0,2612 x 200 |
| Domanda | 0,2697 x 100 |
| Min-Max giorno | 0,2412 - 0,2967 |
| Intervallo di 52 settimane | 0,1560 - 2,4200 |
| Volume | |
| Media Volume | 1.084.824 |
| Capitalizzazione | 7,495M |
| Beta (mensile su 5 anni) | 1,62 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,2700 |
| Prossima data utili | 02 apr 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 1,80 |
GlobeNewswireVirios Therapeutics to Present at the ThinkEquity Conference on Thursday, October 19, 2023
ATLANTA, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases such as fibromyalgia and Long-COVID, announced today that Greg Duncan, Chairman and Chief Executive Officer, will present at the annual ThinkEquity Conference on Thursday, October 19, 2023 at 11:00 am ET in New York, NY. The live and archived webcast of the session may b
- GlobeNewswire
Virios Therapeutics Announces Termination of At-The-Market Sales Agreement
ATLANTA, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases such as fibromyalgia and Long-COVID, today announced that it provided notice of termination of the Capital on Demand™ Sales Agreement entered into between the Company and JonesTrading Institutional Services LLC on July 14, 2023 (the “Sales Agreement”). The Company has i
- GlobeNewswire
Virios Therapeutics CEO Greg Duncan to Present at the SHARE™️ Series Investor Event on Monday, September 18, 2023
ATLANTA, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases such as fibromyalgia (“FM”) and Long-COVID (“LC”), announced today that Greg Duncan, Chairman and Chief Executive Officer, will present at the SHARE™️ Series Monday Management Update for investors on Monday, September 18, 2023, at 11:00 am ET. This virtual event combine
